Oppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.Lam commented, "BLUE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Momentum Movers Trader Talk

Too Earlier to Write Off bluebird bio's (BLUE) LentiGlobin in Subset - CowenNovember 5, 2015 3:44 PM bluebird bio (BLUE) LentiGlobin 'Does Work', Maxim Group SaysNovember 5, 2015 1:06 PM bluebird bio (BLUE) Most Severe Beta-Thal Patients Presenting Challenges, Wedbush Comments; PT Lowered to $165November 5, 2015 12:39 PM 'Not Time to Hit Panic Button' on bluebird bio (BLUE), Oppenheimer SaysNovember 5, 2015 12:23 PM bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH UpdateNovember 5, 2015 8:20 AM bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of HematologyNovember 5, 2015 8:00 AM bluebird bio (BLUE) Posts Wider-than-Expected Q3 LossNovember 5, 2015 6:45 AM bluebird bio (BLUE) Bullish View Reiterate at Post Q3 and Ahead of ASH Abstract Data -OppenheimerNovember 5, 2015 6:38 AM Form 8-K bluebird bio, Inc. For: Nov 04November 4, 2015 4:21 PM